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A B S T R A C T
Arylsulfatase A (ASA) is a lysosomal enzyme involved in catabolism of cerebroside-sulfate, major lipid constituent of
oligodendrocyte membranes. Various polymorphisms in ASA gene have been described, leading to different levels of en-
zyme deficiency. Progressive demyelination occurs in metachromatic leukodystrophy (MLD), while the condition of ASA-
-pseudodeficiency (ASA-PD) is suggested to contribute to complex pathogenesis of multiple sclerosis (MS). This work
presents usefulness of genotype-phenotype correlation in estimation of disease severity and progression. The presence of
two most common mutations associated with ASA-PD was analyzed in 56 patients with diagnosis of relapsing-remitting
multiple sclerosis, by polymerase chain reaction restriction fragment length polymorphism method. In MS patients con-
firmed as ASA-PD mutations carriers, arylsulfatase activity was determined in leukocyte homogenates by spectrophoto-
metry. To determine whether there is a difference between disability level and/or disease progression in patients with or
without mutations we have estimated disability level using Expanded disability status scale (EDSS) and disease pro-
gression using Multiple sclerosis severity score (MSSS). Correlation of genotypes and disease progression was statisti-
cally analyzed by Kruskal-Wallis test. Patients showing higher MSSS score and found to be carriers of both analyzed
ASA-PD mutations were additionally examined using conventional magnetic resonance (MR) techniques. The presence
of either one or both mutations was determined in 13 patients. Lower ASA activities were observed in all MS patients car-
rying the mutations. Nine of the mutations carriers had mild disability (EDSS=0–4.0), 1 had moderate disability
(EDSS=4.5–5.5), and 3 had severe disability (EDSS6.0). On the other hand, only 3 MS patients who were mutation
carriers showed MSSS values lower than 5.000 while in other MS patients-mutation carriers the MSSS values ranged
from 5.267 to 9.453. Comparison of MR findings between MS patients, mutations carrier vs. non-carrier, matched for
sex, age and disease duration, showed that the total number of lesions and the number of hypointense lesions on T1-
-weighted images was greater in MS patient carrying the ASA-PDmutations. Our results on genotype-phenotype correla-
tion analysis indicate a possible contribution of detected arylsulfatase A gene polymorphisms to the clinical severity of
multiple sclerosis, estimated by EDSS, MSSS and MR findings. The MSSS proved to be more appropriate indicator of
disease progression and should be more frequently used in clinical practice especially for comparison of disease progres-
sion in different groups of patients and identification of factors that may influence disease progression such as the pres-
ence of gene polymorphisms.
Key words: multiple sclerosis, arylsulfatase A, gene polymorphisms, genotype-phenotype correlation, disease pro-
gression, multiple sclerosis severity score, magnetic resonance techniques
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Introduction
Arylsulfatase A (ASA, EC 3.1.6.1) is a lysosomal en-
zyme involved in catabolism of cerebroside-sulfate1. This
major lipid constituent of oligodendrocyte membranes
contributes to maintenance of myelin sheath integrity1,2.
Various polymorphisms in ASA gene have been descri-
bed, leading to different levels of enzyme deficiency3,4.
Progressive demyelination occurs in metachromatic leu-
kodystrophy (MLD) due to lysosomal storage of sulfatide
which mainly accumulates in oligodendrocytes and Sch-
wann cells1,5,6. Interestingly, low ASA activities have also
been reported in healthy individuals without clinical
signs of MLD, due to condition termed ASA pseudo-
deficiency (ASA-PD)1,7. Two mutations in the ASA gene,
responsible for the majority of ASA-PD alleles, are desig-
nated as N350S and 1524+95 A-G mutation7. Frequency
of these two mutations is reported to be relatively high in
different populations of Caucasian origin (7.3–15 %)7; in
the Croatian population it has been previously estimated
at 6.4 % for N350S and 2.8 % for 1524+95 A-Gmutation8.
The ASA-PD condition is suggested to contribute to
complex pathogenesis of multiple sclerosis (MS), a chro-
nic neurological disorder characterized by demyelination
in central nervous system9. It has been hypothesized that
different mutations in ASA gene can influence cell vul-
nerability and thus facilitate main pathologic process/
mechanism occurring in multiple sclerosis. By suggested
mechanism, mutations associated with ASA-PD may cau-
se death of small populations of oligodendrocytes and re-
lease myelin antigens which may activate immune sys-
tem. Genotype-phenotype correlation is thus useful in
estimation of disease severity and progression, and can
be more accurately analyzed using recently introduced
Multiple sclerosis severity score method (MSSS)10. The
MSSS method has been developed since there is no con-
sensus method for determining progression of disability
in MS patients when each patient has had only a single
assessment of disability estimated by Kurtzke expanded
disability status scale (EDSS)11 in the course of the dis-
ease. This MSSS method relates scores on the EDSS to
the distribution of disability in patients with comparable
disease durations. It is a powerful method for detecting
different rates of disease progression in different groups
of patients.
The aim of this work was to analyze the impact of de-
tected polymorphisms in arylsulfatase A gene to the clin-
ical severity of multiple sclerosis, estimated by EDSS,
MSSS and MR findings. The work supports the utiliza-
tion of genotype-phenotype correlation analysis which provi-
des useful data for estimation of disease progression and
identification of factors influencing disease progression.
Patients and Methods
We have analyzed the presence of two most common
mutations associated with ASA-PD (N350S and 1524+95
A-G) in 56 patients with diagnosis of relapsing-remitting
multiple sclerosis (RRMS). The patients were recruited
at the University Department of Neurology, »Sveti Duh«
General Hospital, Zagreb. The patient group comprised
of 40 females (age range: 22–57 years) and 16 males (age
range: 18–68 years). The clinical diagnosis of multiple
sclerosis was given in accordance with McDonald’s cri-
teria12,13. Blood samples were collected by venipuncture
during morning hours and before any medications were
given. The study was approved by the Hospital ethical
committee and informed consent was taken from each
patient.
Determination of mutations associated with
arylsulfatase A pseudodeficiency
The presence of ASA-PD mutations was determined
by polymerase chain reaction restriction fragment length
polymorphism method (PCR-RFLP), as previously des-
cribed7. Genomic DNA was extracted from whole blood
samples using modified standard salting out procedure14.
After PCR amplification, RFLP was performed using
BsrSI restriction enzyme for the N350S mutation and
DdeI restriction enzyme for the 1524+95 A-G mutation
(Figure 1). In the presence of N350S mutation, a BsrSI
restriction site is created and a 275 bp amplified frag-
ment yields 161 bp and 114 bp fragments. In the case of
1524+95 A-G mutation, a DdeI restriction site is gener-
ated, and 114 bp amplified fragment is cleaved to two
smaller fragments of 97 bp and 17 bp.
Determination of arylsulfatase A activity in
leukocyte homogenates
Leukocytes were isolated from blood samples of the
patients found to be ASA-PD mutations carriers. Leuko-
cyte pellets were dispersed in 0.25% Triton X-100 and ho-
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Fig. 1. Detection of mutations associated with arylsulfatase A
pseudodeficiency: a) N350S and b) 1524+95 A-G. The results of
PCR-RFLP analysis are shown for several samples derived from
patients with diagnosis of multiple sclerosis. Specific restriction
products were separated by agarose gel-electrophoresis and visu-
alized by ethidium bromide. Left panel: lanes 1–3 show heterozy-
gous N350S genotype (275 bp amplified fragment yields 161 bp
and 114 bp fragments in the presence of mutation). Right panel:
lanes 1–4 and 6 are homozygous for non-mutated genotype and
lane 5 is a heterozygous 1524+95 A-G genotype (in the presence
of mutation, 114 bp amplified fragment is cleaved to two smaller
fragments of 97 bp and 17 bp, the latter not visible on gel because
of its small size). St25 and St100 – DNA standards (25 bp and 100
bp), bp – base pairs.
mogenized. Proteins were determined in leukocyte ho-
mogenates according to the method of Lowry15, using
bovine serum albumin (BSA, 1 mgmL–1) as a standard. The ac-
tivity of arylsulfatase A was measured by spectrophotometry
(l=515 nm) using p-nitrocatechol sulfate as chromo-
genic substrate16. The results on arylsulfatase A activity
were expressed as nanomoles of degraded substrate per
hour per milligram protein (nmol h–1 mg–1).
Estimation of disability level and disease
progression in patients with multiple sclerosis
To determine whether there is a difference between
disability level and/or disease progression in patients
with or without mutations we have estimated disability
level using Expanded disability status scale11 as well as
disease progression using Multiple sclerosis severity sco-
re10 for all patients. Correlation of genotypes and disease
progression was statistically analyzed by Kruskal-Wallis
test (MSSS test, computer programme, version 3.0)17.
Magnetic resonance imaging techniques
A preliminary qualitative comparison of radiological
findings was made using MR exams of one patient with
mutation and of an age, sex and disease duration corre-
sponding control patient. Both exams were done using
conventional MR techniques (T1-, T2-weighted and FLAIR
sequences in multiple planes, with gadolinium enhance-
ment). Imaging markers of disease severity were graded,
namely atrophy, number of hyperintense lesions on T2-
-weighted images, number of hypointense lesions on
T1-weighted images, and number of gadolinium enhanc-
ing lesions.
Results
The presence of either one or both analyzed ASA-PD
mutations was determined in 13 out of 56 MS patients
(Figure 1). All 13 MS patients with mutations were found
to be heterozygous carriers of either/both mutations. De-
mographic characteristics of 13 MS patients (gender, age,
disease duration) found to be ASA-PD mutation carriers
are given in Table 1. Both ASA-PD mutations were de-
tected in 8 MS patients, only N350S mutation was found
in 4 patients, while 1 patient carried only 1524+95 A-G
mutation (Table 2).
The correlation between genotype and enzyme activ-
ity was analyzed in the group of MS patients-mutations
carriers (Table 2). Determined ASA activities in 13 MS
patients-mutations carriers ranged from 57–137 nmol
h–1 mg–1 (median value: 83.0 nmol h–1 mg–1) and were
found to be in the lower part of the ASA activity refer-
ence range (60–300 nmol h–1 mg–1)1,4. In 4 MS patients,
heterozygous carriers of only the N350S mutation, ASA
activities were in the range of 82–121 nmol h–1 mg–1 (me-
dian value: 93.0 nmol h–1mg–1); in 8 MS patients, carriers
of both mutations, the range of ASA activities was 57–137
nmol h–1 mg–1 (median value: 83.5 nmol h–1 mg–1); ASA
activity was also low in 1 patient-heterozygous carrier of
only 1524+95 A-G mutation (62 nmol h–1 mg–1).
Estimation of disability level using Expanded disabil-
ity status scale showed that 9 of the mutations carriers
had mild disability (EDSS=0–4.0), 1 had moderate disabil-
ity (EDSS=4.5–5.5), and 3 had severe disability (EDSS
6.0) (Table 3). Although we found no statistically signifi-
cant correlation of genotypes and MSSS in the group of
56 MS patients (Kruskal-Wallis test), we observed that
only 3 MS patients who were mutation carriers showed
MSSS values lower than 5.000 while in other MS pa-
tients-mutation carriers the MSSS value ranged from
5.267 to 9.453 (Table 3).
Patients found to be carriers of both analyzed ASA-
-PD mutations and showing higher MSSS score were ad-
ditionally examined using conventional magnetic reso-
nance techniques. Comparison of MR findings between
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TABLE 1
DEMOGRAPHIC CHARACTERISTICS OF MULTIPLE SCLEROSIS
PATIENTS – CARRIERS OF ARYLSULFATASE A MUTATIONS
Gender
Male
(N=3)
Female
(N=10)
Age range (years) 34–47 26–57
Mean age (years) 52.3 43.3
Duration of the disease (range in years) 8–15 1–12
Duration of the disease (mean in years) 11 5.8
TABLE 2
CORRELATION OF DETECTED MUTATIONS AND
ARYLSULFATASE A ACTIVITY IN MULTIPLE SCLEROSIS
PATIENTS
Detected mutation
in arylsulfatase A
gene
MS patients-muta-
tion carriers (N=13)
Arylsulfatase A ac-
tivity (nmol h–1 mg–1)
median (range)
N350S and
1524+95 A-G
8 83 (57–137)
N350S 4 93 (82–121)
1524+95 A-G 1 62
MS – multiple sclerosis
Fig. 2. Axial T1-weighted MR images in multiple sclerosis pa-
tients confirmed as a) arylsulfatase A mutations carrier and b)
arylsulfatase A mutations non-carrier, matched for age, gender
and disease duration. Note white matter »black holes« (marked
by arrows) in a) patient with mutations.
MS patients, mutations carrier vs. non-carrier, matched
for sex, age and disease duration, showed no significant
volume loss of brain tissue in both patients. However, the
patient with mutation had greater total number of le-
sions in all 3 assessed categories (hyperintense lesions on
T2-weighted images, hypointense lesions on T1-weighted
images, enhancing lesions) and greater number of lesions
in every separate category. Most notable difference was
in number of hypointense lesions on T1-weighted images
as the patient with mutation had many such lesions and
control patient none (Figure 2).
Discussion and Conclusion
This work indicates the advantages of genotype-phe-
notype correlation analysis supported by MSSS estima-
tion and MR findings in patients with relapsing-remit-
ting multiple sclerosis. We analyzed the influence of
arylsulfatase A gene polymorphisms to the severity and
progression of disease in a group of MS patients. We
found that MS patients who were carriers of mutations
associated with arylsulfatase A pseudodeficiency also ex-
hibited lower enzyme activities. Genotype-phenotype
correlation analysis was completed by estimation of dis-
ability level and disease progression using EDSS and
MSSS, and preliminary qualitative analysis of magnetic
resonance findings.
Possible contribution of arylsulfatase A gene polymor-
phisms to the complex pathogenesis of neurodegenera-
tive disorders has been previously discussed8,18–20. Differ-
ent levels of enzyme deficiency, due to mutations in ASA
gene, could lead to long-term accumulation of non-de-
graded substrate and thus influence the cellular vulnera-
bility. In multiple sclerosis, the same mechanism could
underlie a death of oligodendrocyte subpopulations thus
enabling liberation of myelin antigens and stimulation of
immune response9. In this study, the correlation between
ASA-PD genotype and phenotype was indeed confirmed,
as lower enzyme activities were observed in ASA-PD mu-
tation carriers.
In order to investigate influence of analyzed ASA-PD
gene polymorphisms to the severity and progression of
disease, we estimated disability level in MS patients by
EDSS and MSSS. Although EDSS is useful in determin-
ing clinical signs of disability level in multiple sclerosis, it
shows limitations related to single assessments in the
course of the disease which give no insight into disease
progression. Moreover, EDSS may vary significantly de-
pending whether estimated during relapse or remission
of the disease. Recently introduced Multiple sclerosis se-
verity score method has been developed for the purposes
of more accurate estimation of disease progression10. The
MSSS relates scores on the EDSS to the distribution of
disability in patients with comparable disease durations.
Since MSSS method takes into account disability as well
as the duration of the disease it is a more appropriate in-
dicator of disease progression than EDSS which presents
only the disability level. The MSSS is also a powerful
method used for correlation analysis of groups of pa-
tients with different genotypes and disease progression
and is proven to be useful for identifying factors that may
influence disease progression such as the presence of
gene polymorphisms. In our study, MSSS was helpful in
estimation of disease severity as it confirmed that MS pa-
tients-mutations carriers indeed showed higher MSSS
values indicating faster disease progression.
Additionally, the analysis of brain magnetic resonance
imaging data is important in clarifying the correlation of
morphological changes (demyelination) with the pres-
ence of gene polymorphisms. Our preliminary qualitative
analysis of radiological findings showed that patient-mu-
tations carrier compared with patient-mutation non-car-
rier had greater total number of demyelinating lesions,
with most notable difference in number of hypointense
lesions on T1-weighted images. Lesions on T1-weighted
images are seen as areas of low signal intensity compared
to normal-appearing white matter. These so-called »black
holes« have various pathological substrates depending
on their age. In acute stage this hypointensity represents
edema with or without myelin destruction and axonal
loss. In most cases, these acute lesions become isointense
and disappear with resolution of inflammatory process,
while only smaller proportion develop into persisting or
chronic lesions, which correlate pathologically with areas
of irreversible tissue damage. It is known that chronic
»black holes« are more frequent in patients with progres-
sive disease than in those with relapsing-remitting dis-
ease and it has been suggested that their number could
serve as a surrogate marker of disability progression21,22.
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TABLE 3
ESTIMATION OF DISABILITY LEVEL AND DISEASE
PROGRESSION IN MULTIPLE SCLEROSIS PATIENTS-CARRIERS
OF ARYLSULFATASE A MUTATIONS
Mutation
N350S
Mutation
1524+95 A-G
EDSS MSSS
Mild disability (0–4.0)
M NM 2.0 5.866
M M 2.0 5.866
M M 3.0 4.568
NM M 3.0 4.966
M NM 3.0 5.382
M M 4.0 4.621
M M 4.0 5.267
M NM 4.0 7.652
M M 4.0 8.138
Moderate disability (4.5–5.5)
M M 5.0 6.501
Severe disability (6.0)
M NM 6.0 7.652
M M 7.0 8.169
M M 7.0 9.453
M – mutation, NM – no mutation, EDSS – Expanded disability
status scale, MSSS – Multiple sclerosis severity score
Here presented radiological analysis in which MS pa-
tient/mutation carrier was compared with MS patient/
mutation non-carrier, carefully matched for age, gender,
disease duration and MSSS value, suggests the correla-
tion of present ASA-PD mutations, low ASA activity,
high MSSS value and morphological finding of irrevers-
ible axonal degeneration. Further morphological investi-
gation should include larger group of MS patients, and
utilize the advantage of more powerful MR device and
three-dimensional MR volumetric analysis of lesions.
In conclusion, our results indicate a possible contribu-
tion of detected arylsulfatase A gene polymorphisms to
the clinical severity of multiple sclerosis. The MSSS
proved to be more appropriate indicator of disease pro-
gression and should be more frequently used in clinical
practice especially for comparison of disease progression
in different groups of patients and identification of fac-
tors that may influence disease progression such as the
presence of gene polymorphisms. Presented approach of
genotype-phenotype analysis enabled more accurate esti-
mation of disease severity and progression in here inves-
tigated group of MS patients; also it served for compari-
son of disease progression in different groups of patients
and identification of factors that may influence disease
progression.
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POLIMORFIZMI U GENU ZA ARILSULFATAZU A I RELAPSNO-REMITIRAJU]A MULTIPLA
SKLEROZA: KORELACIJA GENOTIPA I FENOTIPA U SVRHU PROCJENE PROGRESIJE BOLESTI
S A @ E T A K
Arilsulfataza A (ASA) je lizosomski enzim uklju~en u razgradnju cerebrozid-sulfata, glavnog lipidnog sastojka oligo-
dendrocitnih membrana. Opisani su brojni polimorfizmi u genu za arilsulfatazu A koji imaju za posljedicu razli~ite
razine nedostatne aktivnosti enzima. Tako se kod metakromatske leukodistrofije (MLD) razvija progresivna demijelini-
zacija, a za ASA-pseudodeficijenciju (ASA-PD) pretpostavlja se da je povezana sa slo`enom patogenezom multiple skle-
roze (MS). Ovaj rad ukazuje na korisnost analize korelacije genotipa i fenotipa u procjeni te`ine i progresije bolesti.
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Prisutnost dviju naj~e{}ih mutacija povezanih s ASA-PD ispitivana je metodom analize duljine restrikcijskih fragme-
nata u 56 pacijenata s dijagnozom relapsno-remitiraju}eg oblika multiple skleroze. U pacijenata za koje je utvr|eno da
su nositelji ASA-PD mutacija, odre|ena je aktivnost arilsulfataze A u leukocitnim homogenatima spektrofotometrij-
skom metodom. Utvr|ivanje razlika stupnja invalidnosti i/ili progresije bolesti u pacijenata sa ili bez ASA-PD mutacija
temeljeno je na procjeni stupnja invalidnosti primjenom EDSS (Expanded disability status scale) i MSSS (Multiple scle-
rosis severity score) zbroja. Korelacija genotipa i progresije bolesti analizirana je statisti~ki Kruskal-Wallis-ovim tes-
tom. Pacijenti s vi{im MSSS vrijednostima za koje je utvr|eno da ujedno imaju obje ASA-PD mutacije dodatno su
pregledani konvencionalnim tehnikama magnetske rezonancije (MR). Prisutnost jedne ili obje ASA-PD mutacije utvr-
|ena je u 13 pacijenata. U ovih je pacijenata na|ena i ni`a aktivnost arilsulfataze A. Tako|er je u 9 pacijenata zabilje-
`ena blaga invalidnost (EDSS=0–4,0), 1 je pacijent imao umjereni stupanj invalidnosti (EDSS=4,5–5,5), a 3 pacijenata
te{ku invalidnost (EDSS6,0). Samo 3 pacijenta nositelja mutacija imali su MSSS vrijednost ni`u od 5,000, dok su
MSSS vrijednosti ostalih nositelja mutacija bile u rasponu od 5,267 do 9,453. Usporedba nalaza MR-e izme|u pacijenta
nositelja mutacija i pacijenta bez mutacija, uskla|enih po spolu, dobi i duljini trajanja bolesti, pokazala je da je ukupan
broj lezija kao i broj hipointenzivnih lezija na T1-snimkama ve}i u pacijenta koji je nositelj ASA-PD mutacija. Rezultati
analize korelacije genotipa i fenotipa ukazuju da utvr|eni polimorfizmi u genu za arilsulfatazu A mogu utjecati na
te`inu klini~ke slike multiple skleroze, procjenjenu pomo}u EDSS, MSSS i MR nalaza. MSSS zbroj dokazan je kao bolji
pokazatelj progresije bolesti i trebao bi se ~e{}e koristiti u klini~koj praksi naro~ito za usporedbu progresije bolesti
me|u razli~itim skupinama bolesnika te za prepoznavanje faktora koji mogu utjecati na progresiju bolesti poput pri-
sutnosti genskih polimorfizama.
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